BioNTech SE

BioNTech SE is a German biotechnology company founded in 2008 and headquartered in Mainz, Germany. The company focuses on developing innovative immunotherapies that utilize the immune system to treat cancer and infectious diseases, with a strong emphasis on messenger RNA (mRNA) technology. BioNTech's product portfolio includes mRNA-based vaccines and therapeutics, such as Comirnaty, the first approved mRNA vaccine for COVID-19, and personalized cancer immunotherapies that create individualized vaccines targeting specific tumor profiles. The company also develops cell therapies, including CAR-T programs, and protein-based therapeutics. BioNTech operates a comprehensive technology platform that integrates various fields, including GMP manufacturing, clinical development, and data science, to enhance innovation. The company collaborates with global pharmaceutical partners to advance its clinical pipeline and ensure equitable access to medicines. BioNTech is committed to addressing unmet medical needs and has achieved significant milestones, including the authorization of its COVID-19 vaccine and the construction of a manufacturing facility in Africa to support global vaccine distribution.